Stock 2616 CSTONE PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
0.9 HKD 0.00% Intraday chart for CStone Pharmaceuticals +5.88% -60.35%
04-24 Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
04-23 CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma
China Approves CStone's Lymphoma Medication
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma
CStone CEO to Boost Share Count; Shares Fall 9%
CStone Pharmaceuticals Announces Registrational Trial of Sugemalimab in First-Line Gastric or Gastroesophageal Junction Adenocarcinoma Met Primary Endpoint of Overall Survival
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2616 Stock
  4. News CStone Pharmaceuticals
  5. Other languages